Abstract PD5-3: Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
2012 ◽
Vol 71
(1)
◽
pp. 63-72
◽
2010 ◽
Vol 125
(1)
◽
pp. 137-143
◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 644-644
◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 644-644
2015 ◽
Vol 154
(2)
◽
pp. 287-297
◽